Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Gastroenterology. 2009 Mar 18;137(1):209–220. doi: 10.1053/j.gastro.2009.03.007

Figure 3. Therapeutic efficacy of TLR2 agonist in acute inflammatory injury is dependent on anti-apoptotic TFF3.

Figure 3

(A–D) TFF3+/+ or TFF3−/− mice [129S2/SvPaf] (n=10 per group) received 2.5% DSS for 5 days followed by treatment with PCSK 150µg/ml or water for 7 subsequent days. Mice were sacrificed on days 8 or 12. Data are presented as means ± SEM. (−PCSK) vs. (+PCSK): *p<0.05; **p<0.01; ***p<0.001; +p>0.05. (A) TUNEL (FITC: green) assay of colonic tissues using confocal immunofluorescence on day 12 after DSS exposure with or without subsequent PCSK therapy in TFF3−/− mice. Cells were counterstained with PI for nuclei (rhodamine: red) and anti-pancytokeratin (CY5: white) specific for IEC (40x/1.3, oil, scan zoom 0.7). Representative immunofluorescent images are shown; green arrows indicate apoptotic cells. Evolution of (B) body weight changes and (C) histology scores during DSS colitis and subsequent treatment with or without PCSK. (D) Preservation of ZO-1 (CY5: white) – associated IEC barrier integrity after PCSK treatment in DSS-TFF3−/− on day 12, as assessed by confocal immunofluorescence analysis (40x/1.3 oil, scan zoom 1.0). Arrow indicates ZO-1 staining and star subepithelial infiltrate, respectively. Cells were counterstained with DAPI for nuclei (blue) and anti-pancytokeratin (FITC: green), as presented in inserts.